Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: Dr Andersohn and colleagues suggest that the highest risks of cardiovascular events with celecoxib are seen in European study populations, where the CYP2C9*3 allele associated with slow metabolism of celecoxib (and by implication an increased risk of thrombosis) may occur with a frequency of as much as 16%. This is an interesting suggestion, but we can speculate that it may not be the most likely explanation for the heterogeneity observed in the study results.
Henry D, McGettigan P. Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply. JAMA. 2007;297(6):586-588. doi:10.1001/jama.297.6.587